Yumi Imai

Dr. Yumi Imai

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1994 in Diabetes
Verified
Journal Article
Closed access
PDF file
STSimeon I Taylor
Simeon I Taylor
DADomenico Accili
Domenico Accili
YIYumi Imai
Yumi Imai

16 January 2014 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MBMatthew J. Butcher
Matthew J. Butcher
DHDaniel Hallinger
Daniel Hallinger
EGEden Garcia
Eden Garcia
YMYui Machida
Yui Machida
SCSwarup Chakrabarti
Swarup Chakrabarti
YIYumi Imai
Yumi Imai

1 May 2007 in Gastroenterology
Verified
Journal Article
Closed access
YIYumi Imai
Yumi Imai
GVGladys M. Varela
Gladys M. Varela
MJMalaka B. Jackson
Malaka B. Jackson
MGMark J. Graham
Mark J. Graham
RCRosanne M. Crooke
Rosanne M. Crooke
RARexford S. Ahima
Rexford S. Ahima

1 March 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Divya KumarDivya Kumar
Divya Kumar
AAAmon Asgharpour
Amon Asgharpour
FMFaridoddin Mirshahi
Faridoddin Mirshahi
SPSo Hyun Park
So Hyun Park
SLSichen Liu
Sichen Liu
ASArun Sanyal
Arun Sanyal
The physiological role of the TGR5 receptor in the pancreas is not fully understood. We previously showed that activation of TGR5 in pancreatic β cells by bile acids induces insulin secretion. Glucagon released from pancreatic α cells and glucagon-like peptide 1 (GLP-1) released from intestinal L cells regulate insulin secretion. Both glucagon and GLP-1 are derived from alternate splicing of a common precursor, proglucagon by PC2 and PC1, respectively. We investigated whether TGR5 activation in pancreatic α cells enhances hyperglycemia-induced PC1 expression thereby releasing GLP-1, which in turn increases β cell mass and function in a paracrine manner. TGR5 activation augmented a hyperglycemia-induced switch from glucagon to GLP-1 synthesis in human and mouse islet α cells by GS/cAMP/PKA/cAMP-response element-binding protein-dependent activation of PC1. Furthermore, TGR5-induced GLP-1 release from α cells was via an Epac-mediated PKA-independent mechanism. Administration of the TGR5 agonist, INT-777, to db/db mice attenuated the increase in body weight and improved glucose tolerance and insulin sensitivity. INT-777 augmented PC1 expression in α cells and stimulated GLP-1 release from islets of db/db mice compared with control. INT-777 also increased pancreatic β cell proliferation and insulin synthesis. The effect of TGR5-mediated GLP-1 from α cells on insulin release from islets could be blocked by GLP-1 receptor antagonist. These results suggest that TGR5 activation mediates cross-talk between α and β cells by switching from glucagon to GLP-1 to restore β cell mass and function under hyperglycemic conditions. Thus, INT-777-mediated TGR5 activation could be leveraged as a novel way to treat type 2 diabetes mellitus.

1 July 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KRKristina I. Rother
Kristina I. Rother
YIYumi Imai
Yumi Imai
MCMatilde Caruso
Matilde Caruso
FBFrancesco Beguinot
Francesco Beguinot
Pietro FormisanoPietro Formisano
Pietro Formisano
DADomenico Accili
Domenico Accili
Insulin receptor substrates (IRSs) are tyrosine-phosphorylated following stimulation with insulin, insulin-like growth factors (IGFs), and interleukins. A key question is whether different IRSs play different roles to mediate insulin’s metabolic and growth-promoting effects. In a novel system of insulin receptor-deficient hepatocytes, insulin fails to (i) stimulate glucose phosphorylation, (ii) enhance glycogen synthesis, (iii) suppress glucose production, and (iv) promote mitogenesis. However, insulin’s ability to induce IRS-1 and gab-1 phosphorylation and binding to phosphatidylinositol (PI) 3-kinase is unaffected, by virtue of the compensatory actions of IGF-1 receptors. In contrast, phosphorylation of IRS-2 and generation of IRS-2/PI 3-kinase complexes are markedly reduced. Thus, absence of insulin receptors selectively reduces IRS-2, but not IRS-1 phosphorylation, and the impairment of IRS-2 activation is associated with lack of insulin effects. To address whether phosphorylation of additional IRSs is also affected, we analyzed phosphotyrosine-containing proteins in PI 3-kinase immunoprecipitates from insulin-treated cells. However, these experiments indicate that IRS-1 and IRS-2 are the main PI 3-kinase-bound proteins in hepatocytes. These data identify IRS-2 as the main effector of both the metabolic and growth-promoting actions of insulin through PI 3-kinase in hepatocytes, and IRS-1 as the main substrate mediating the mitogenic actions of IGF-1 receptors.

1 July 2012 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
JWJessica R. Weaver
Jessica R. Weaver
THTheodore R. Holman
Theodore R. Holman
YIYumi Imai
Yumi Imai
AJAjit Jadhav
Ajit Jadhav
VKVictor Kenyon
Victor Kenyon
DTDavid A. Taylor-Fishwick
David A. Taylor-Fishwick